Cargando…
Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094090/ https://www.ncbi.nlm.nih.gov/pubmed/33054134 http://dx.doi.org/10.3324/haematol.2020.267526 |
| _version_ | 1783687945341894656 |
|---|---|
| author | Wei, Hui Zhou, Chunlin Lin, Dong Liu, Bingcheng Li, Yan Zhao, Xingli Wei, Shuning Gong, Benfa Liu, Kaiqi Gong, Xiaoyuan Liu, Yuntao Zhang, Guangji Chen, Jiayuan Zhang, Junping Jin, Jingjing Qiu, Shaowei Gu, Runxia Wang, Ying Mi, Yingchang Wang, Jianxiang |
| author_facet | Wei, Hui Zhou, Chunlin Lin, Dong Liu, Bingcheng Li, Yan Zhao, Xingli Wei, Shuning Gong, Benfa Liu, Kaiqi Gong, Xiaoyuan Liu, Yuntao Zhang, Guangji Chen, Jiayuan Zhang, Junping Jin, Jingjing Qiu, Shaowei Gu, Runxia Wang, Ying Mi, Yingchang Wang, Jianxiang |
| author_sort | Wei, Hui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8094090 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80940902021-05-06 Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia Wei, Hui Zhou, Chunlin Lin, Dong Liu, Bingcheng Li, Yan Zhao, Xingli Wei, Shuning Gong, Benfa Liu, Kaiqi Gong, Xiaoyuan Liu, Yuntao Zhang, Guangji Chen, Jiayuan Zhang, Junping Jin, Jingjing Qiu, Shaowei Gu, Runxia Wang, Ying Mi, Yingchang Wang, Jianxiang Haematologica Letters to the Editor Fondazione Ferrata Storti 2020-09-28 /pmc/articles/PMC8094090/ /pubmed/33054134 http://dx.doi.org/10.3324/haematol.2020.267526 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Wei, Hui Zhou, Chunlin Lin, Dong Liu, Bingcheng Li, Yan Zhao, Xingli Wei, Shuning Gong, Benfa Liu, Kaiqi Gong, Xiaoyuan Liu, Yuntao Zhang, Guangji Chen, Jiayuan Zhang, Junping Jin, Jingjing Qiu, Shaowei Gu, Runxia Wang, Ying Mi, Yingchang Wang, Jianxiang Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title | Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title_full | Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title_fullStr | Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title_full_unstemmed | Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title_short | Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| title_sort | benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094090/ https://www.ncbi.nlm.nih.gov/pubmed/33054134 http://dx.doi.org/10.3324/haematol.2020.267526 |
| work_keys_str_mv | AT weihui benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT zhouchunlin benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT lindong benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT liubingcheng benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT liyan benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT zhaoxingli benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT weishuning benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT gongbenfa benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT liukaiqi benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT gongxiaoyuan benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT liuyuntao benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT zhangguangji benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT chenjiayuan benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT zhangjunping benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT jinjingjing benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT qiushaowei benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT gurunxia benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT wangying benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT miyingchang benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia AT wangjianxiang benefitofintermediatedosecytarabinecontaininginductioninmolecularsubgroupsofacutemyeloidleukemia |